Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

After a median follow-up of 10.5 months, the estimated rate of overall survival at 12 months was 69.2% (95% confidence interval [CI], 64.1 to 73.8) in the pembrolizumab-combination group versus 49.4% (95% CI, 42.1 to 56.2) in the placebo-combination group (hazard ratio for death, 0.49; 95% CI, 0.38 to 0.64; P<0.001). Improvement in overall survival was seen across all PD-L1 categories that were evaluated. Median progression-free survival was 8.8 months (95% CI, 7.6 to 9.2) in the pembrolizumab-combination group and 4.9 months (95% CI, 4.7 to 5.5) in the placebo-combination group (hazard ratio for disease progression or death, 0.52; 95% CI, 0.43 to 0.64; P<0.001). Adverse events of grade 3 or higher occurred in 67.2% of the patients in the pembrolizumab-combination group and in 65.8% of those in the placebo-combination group.

經過10.5個月的中位隨訪後，pembrolizumab-合併組的12個月總生存率為69.2％（95％置信區間[CI]，64.1至73.8），而49.4％（95％CI，42.11，42.11）至56.2）在安慰劑組合組中（死亡危險比，0.49； 95％CI，0.38至0.64； p <0.001）。在評估的所有PD-L1類別中都可以看到總體生存的提高。pembrolizumab - 組合組中的無進展生存期為8.8個月（95％CI，7.6至9.2），安慰劑組合組中的4.9個月（95％CI，4.7至5.5）（疾病進展或死亡的危險比，危險比率，0.52; 95％CI，0.43至0.64; p <0.001）。在Pembrolizumab組合組中，有67.2％的患者和安慰劑組合組的患者中有67.2％發生了3級或更高級的不良事件。